Entrada Therapeutics Bolsa (NASDAQ: TRDA)

Últimas noticias sobre Entrada Therapeutics (NASDAQ:TRDA) Bolsa

ENTRADA THERAPEUTICS INC

Entrada Therapeutics

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics Inc

WIIM

Xilio Therapeutics shares are trading lower after the company announced it commenced a public offering of pre-funded warrants.

News

SABR

Sabre Agrees With Salamair, Utilizing Sabre's Marketplace To Enhance Salamair's Global Visibility, Expand Market Reach, And Drive Revenue Growth

CLEU

China Liberal Education shares are trading lower after the company announced it will be suspended from Nasdaq for failing to address a 20-F delinquency filing.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

NIVF

NewGen To Invest  $30M In Solana Digital Asset Staking

Safe &amp; Green Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) ("Safe &amp; Green Holdings" or the "Company"), a leading designer and fabricator of modular structures, and a developer of diversified platforms that advance critical infrastructure through sustainable innovation, announces the signing of a non-binding Letter of Intent ("LOI") to acquire Giant Containers Inc., a recognized leader in modular, container-based infrastructure solutions.
Under the terms of the LOI, Safe &amp; Green will acquire 100% of the issued and outstanding shares of Giant Containers. The transaction also includes the appointment of Giant's CEO, Daniel Kroft, as Vice President of Business Development at Safe &amp; Green.
The proposed acquisition remains subject to customary conditions, including satisfactory due diligence, final negotiation and execution of definitive agreements, board approvals, and any necessary regulatory approvals. Final terms in the definitive agreements are subject to change from the LOI, closing is anticipated on or before June 15, 2025.

SGBX

Safe & Green To Acquire 100% Of Issued And Outstanding Shares Of Giant Containers; Terms Not Disclosed

PSTV

PLUS Therapeutics shares are trading higher. The company reported Q1 financial results.

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains Seacoast Banking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBCF#NASDAQ">SBCF</a>) with a Outperform and raises the price target from $31 to $32.

Price Target

Analyst Ratings

SBCF

Keefe, Bruyette & Woods Maintains Outperform on Seacoast Banking, Raises Price Target to $32

Guidance

The Campbell's Sees FY25 Adjusted EPS To Be At The Low End Of The Guidance Range Due To The Slower Than Anticipated Recovery In The Snacks Business, Excluding The Impact Of Tariffs

The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) mNexspike&nbsp;(mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged 12-64 years with at least one or more underlying risk factor as defined by the Centers for Disease <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Control and Prevention (CDC)</a>.
&#8220;The FDA approval of our third product, mNEXSPIKE&#8230;,&#8221; said Stéphane Bancel, Chief <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/ac45708511/moderna-receives-u-s-fda-approval-for-covid-19-vaccine-mnexspike" rel="noreferrer noopener">Executive Officer of Moderna</a>.
The FDA&#8217;s approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 trial, which enrolled approximately 11,400 participants aged 12 years and older.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45624037/robert-f-kennedy-jr-says-cdc-drops-covid-vaccine-for-healthy-pregnant-women-kids" rel="noreferrer noopener">Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For &#8216;Healthy&#8217; Pregnant Women, Children</a>
The primary efficacy objective was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNexspike compared to that after the comparator vaccine, mRNA-1273 (Spikevax), Moderna&#8217;s original COVID-19 vaccine.
Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273.
mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older.
In the Phase 3 trial, mRNA-1283 was found to have a similar safety profile to mRNA-1273, with fewer local reactions and comparable systemic reactions.
The most commonly solicited side effects were injection site pain, fatigue, headache and myalgia.
Moderna expects to have mNexspike available for eligible populations in the U.S. for the 2025-2026 respiratory virus season, alongside Spikevax and mRESVIA, the company&#8217;s approved respiratory syncytial virus (RSV) vaccine.
William Blair writes, &#8220;Approval of mRNA-1283 is an incremental win for Moderna, especially considering HHS Secretary Robert F. Kennedy Jr.&#8217;s negative public opinion on mRNA COVID-19 vaccines, and we continue to see autonomy and data-driven decisions at the FDA.&#8221;
&#8220;We do not see approval of mRNA-1283 as a massive boost to Moderna&#8217;s COVID-19 vaccine sales, which we believe are primarily driven by sentiment surrounding the vaccination market in general, but this is a critical step in the regulatory path for the combo flu/COVID vaccine product, mRNA-1083, which uses mRNA-1283 as the COVID-19 component of its formulation,&#8221; analyst Myles Minter writes.
Analyst Minter says Moderna is still facing challenges from new government policies, including <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45663794/hhs-cancels-590m-moderna-bird-flu-vaccine-deal-casting-uncertainty-over-pandemic-preparedness-effort" rel="noreferrer noopener">losing about $700 million</a> in funding from the Department of Health and Human Services for its bird flu vaccine project.
In addition, William Blair writes that the company&#8217;s goal to break even by 2028 is overly optimistic since it would need to more than double its revenue—based on cash costs—to reach that target.
In May, the FDA approved Novavax, Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) Nuvaxovid for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older and individuals 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19 (e.g. asthma, cancer, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45489838/u-s-fda-approves-bla-for-novavaxs-covid-19-vaccine" rel="noreferrer noopener">diabetes, obesity, smoking)</a>.
Achievement of the U.S. license approval has triggered a&nbsp;$175 million&nbsp;milestone payment from Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).
Price Action: MRNA stock is up 4.82% at $27.84 during the premarket session at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/05/45703385/dell-wins-wall-street-praise-after-12-billion-ai-server-orders-solid-commercial-pc-demand" target="_blank" rel="noreferrer noopener">Dell Wins Wall Street Praise After $12 Billion AI Server Orders, Solid Commercial PC Demand</a></li>
</ul>
Photo by Wolfilser via Shutterstock

Biotech

Large Cap

Health Care

Movers

Trading Ideas

General

MRNA

NVAX

Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals

Contracts

TAOP

Taoping Wins $2.8M Contract To Supply Hunan Xiuxiang Agricultural Technology With Designated Agricultural Products

Citigroup analyst Patrick Cunningham initiates coverage on RPM Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) with a Buy rating and announces Price Target of $135.

Initiation

Citigroup Initiates Coverage On RPM Intl with Buy Rating, Announces Price Target of $135

<ul>
<li>KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scales</li>
<li>Patients taking INGREZZA reported robust and clinically meaningful improvements in physical, social and emotional functioning</li>
<li>Improvements were seen as early as Week 4 after initial treatment with the lowest INGREZZA dose and sustained through Week 24</li>
<li>Even patients with milder uncontrolled movement severity were negatively impacted by their tardive dyskinesia at baseline and demonstrated meaningful improvements in tardive dyskinesia impact with INGREZZA treatment</li>
</ul>
SAN DIEGO, June 2, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439241-1&amp;h=2727807877&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced new data from the Phase 4 KINECT-PROTM open-label study demonstrating robust and sustained improvements in physical, social and emotional functioning in patients with tardive dyskinesia taking once-daily INGREZZA&#xAE; (valbenazine) capsules. KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment, specifically INGREZZA, on tardive dyskinesia using multiple clinically validated scales, including the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439241-1&amp;h=1411550016&amp;u=https%3A%2F%2Fjpro.springeropen.com%2Farticles%2F10.1186%2Fs41687-023-00679-4&amp;a=Tardive+Dyskinesia+Impact+Scale">Tardive Dyskinesia Impact Scale</a>. The Tardive Dyskinesia Impact Scale is the only patient-reported outcome instrument designed for and validated in tardive dyskinesia patients that measures the physical, social and emotional impact of the involuntary movements of the condition. These results were presented at 2025 Psych Congress Elevate in Las Vegas.

NBIX

Neurocrine Biosciences Announces New Data From Phase 4 KINECT-PROTM Open-Label Study Showing Robust, Sustained Improvements In Physical, Social And Emotional Functioning In Patients With Tardive Dyskinesia Taking Once-Daily INGREZZA Capsules

Company's PALISADE-4 Phase 3 trial now expected to read out in the first half of 2026

VTGN

Vistagen Therapeutics Provides Update For U.S. Registration-Directed PALISADE-3 Phase 3 Trial Evaluating Fasedienol For Acute Treatment Of Social Anxiety Disorder

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Hamilton Lane (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) with a Market Perform and lowers the price target from $162 to $155.

HLNE

Keefe, Bruyette & Woods Maintains Market Perform on Hamilton Lane, Lowers Price Target to $155

WETO

Webush International shares are trading higher after the company announced it signed a $300 million XRP treasury management agreement with Samara Alpha.

Ladenburg Thalmann analyst Paul Fremont downgrades NorthWestern Energy Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWE#NASDAQ">NWE</a>) from Buy to Neutral and lowers the price target from $57.5 to $56.

Downgrades

Ladenburg Thalmann Downgrades NorthWestern Energy Group to Neutral, Lowers Price Target to $56

Classover Holdings, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/KIDZ#NASDAQ">KIDZ</a>, KIDZW)) ("Classover" or the "Company"), a leading provider of live, interactive online learning, today announced it has entered into a securities purchase agreement with Solana Growth Ventures LLC for the issuance of up to $500 million in senior secured convertible notes, advancing its strategic initiative to build a Solana (SOL)-based treasury reserve
Key Highlights:
- The securities purchase agreement provides for the issuance of up to $500 million in senior secured convertible notes. An initial closing and funding of $11 million is expected to occur promptly after customary closing conditions have been satisfied.
- The notes may be converted by the holder into the Company's Class B common stock at an initial conversion price equal to 200% of the closing price of the Company's Class B common stock on the trading day immediately prior to the closing date, subject to adjustment as provided for in the notes.
- Under the agreement, Classover is required to allocate up to 80% of the net proceeds toward purchases of SOL (Solana), subject to certain terms and limitations.
- This new agreement complements Classover's previously announced $400 million equity purchase agreement, increasing the Company's total potential financing capacity to $900 million, dedicated to supporting its SOL acquisition strategy.
- Prior to this agreement, Classover had already initiated its SOL reserve strategy, having purchased 6,472 SOL for approximately $1.05 million - marking the first step in its long-term strategy to acquire, hold, and stake Solana ("SOL") tokens.
The Company is also exploring opportunities for acquiring discounted blocks of locked tokens, as part of its broader accumulation and treasury strategy.

KIDZ

KIDZW

Classover Holdings Enters Into Securities Purchase Agreement With Solana Growth Ventures For Issuance Of Up To $500M In Senior Secured Convertible Notes, Advancing Strategic Initiative To Build Solana-Based Treasury Reserve

Management

TELA

TELA Bio Appoints Jeffrey Blizard As President Effective Immediately

Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) will release its first-quarter financial results before the opening <a href="https://www.benzinga.com/quote/DG/earnings">bell on Tuesday, June 3.</a>
Analysts expect the company to report quarterly earnings at $1.49 per share, down from $1.65 per share in the year-ago period. Dollar General projects quarterly revenue of $10.29 billion, compared to $9.91 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 29, UBS analyst Michael Lasser maintained Dollar General with a Buy rating and raised the price target from $95 to $120.
With the recent buzz around Dollar General, some investors may be eyeing potential gains from the company's dividends too. As of now, Dollar General offers an annual dividend yield of 2.43%, which is a quarterly dividend amount of 59 cents per share ($2.36 a year).
To figure out how to earn $500 monthly from Dollar General, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by Dollar General's $2.36 dividend: $6,000 / 2.36 = 2,542 shares.
So, an investor would need to own approximately $247,210 worth of Dollar General, or 2,542 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.158 = 508 shares, or $49,403 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
DG Price Action: Shares of Dollar General gained by 0.2% to close at $97.25 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38289870/top-5-tech-and-telecom-stocks-that-may-rocket-higher-this-month">Top 5 Tech And Telecom Stocks That May Rocket Higher This Month</a></li>
</ul>
Photo: Shutterstock

Long Ideas

How To Earn $500 A Month From Dollar General Stock Ahead Of Q1 Earnings

ARVN

Arvinas shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target from $10 to $9.

Press Releases

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Earnings

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Azenta Announces the Election of Dipal Doshi to its Board of Directors

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Comments

Entrada Therapeutics

Noticias

Últimas noticias sobre Entrada Therapeutics (NASDAQ:TRDA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL